| Date | Time | Source | Headline | Symbol | Company |
| 06/18/2024 | 2:57PM | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:MGRX | Mangoceuticals Inc |
| 06/10/2024 | 1:28PM | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:MGRX | Mangoceuticals Inc |
| 06/06/2024 | 8:30AM | GlobeNewswire Inc. | MangoRx Receives Notice of Acceptance for Patent Application in Australia for Respiratory Illness and Preventive Care Technology | NASDAQ:MGRX | Mangoceuticals Inc |
| 06/05/2024 | 5:15PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:MGRX | Mangoceuticals Inc |
| 06/05/2024 | 5:15PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:MGRX | Mangoceuticals Inc |
| 06/05/2024 | 5:15PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:MGRX | Mangoceuticals Inc |
| 06/04/2024 | 4:00PM | GlobeNewswire Inc. | MangoRx Receives Patent Notice of Allowance in Japan for Revolutionary Preventive Care Technology Acquired from Intramont Technologies | NASDAQ:MGRX | Mangoceuticals Inc |
| 06/04/2024 | 8:00AM | GlobeNewswire Inc. | MangoRx to Introduce “MOJO” Pharmaceutical Compounded Formula Featuring Enclomiphene Citrate and Pregnenolone for Treatment of Low Testosterone and Male Hormone Imbalances | NASDAQ:MGRX | Mangoceuticals Inc |
| 05/28/2024 | 8:30AM | GlobeNewswire Inc. | Mangoceuticals, Inc. Announces Completion of First Batch of Mango ED Products for Marketing and Distribution in Mexico and Latin American Markets | NASDAQ:MGRX | Mangoceuticals Inc |
| 05/23/2024 | 8:30AM | GlobeNewswire Inc. | MangoRx Engages Renown International Digital and Performance Marketing Company Crakmedia to Champion its Digital Marketing Efforts | NASDAQ:MGRX | Mangoceuticals Inc |
| 05/21/2024 | 8:30AM | GlobeNewswire Inc. | MangoRx to Introduce Oral Semaglutide and Tirzepatide in Response to Increasing Patient Demand for GLP-1 Medications | NASDAQ:MGRX | Mangoceuticals Inc |
| 05/16/2024 | 4:40PM | GlobeNewswire Inc. | MangoRx Reports Revenue Growth of 108% in Q1 2024 Fueled by Amplified Customer Acquisition and Early Market Penetration | NASDAQ:MGRX | Mangoceuticals Inc |
| 05/16/2024 | 1:59PM | Edgar (US Regulatory) | Form ARS - Annual Report to Security Holders | NASDAQ:MGRX | Mangoceuticals Inc |
| 05/16/2024 | 9:19AM | Edgar (US Regulatory) | Form DEF 14A - Other definitive proxy statements | NASDAQ:MGRX | Mangoceuticals Inc |
| 05/15/2024 | 4:52PM | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:MGRX | Mangoceuticals Inc |
| 05/14/2024 | 9:00AM | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee benefit plans | NASDAQ:MGRX | Mangoceuticals Inc |
| 05/10/2024 | 12:15AM | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness | NASDAQ:MGRX | Mangoceuticals Inc |
| 05/06/2024 | 5:32PM | Edgar (US Regulatory) | Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] | NASDAQ:MGRX | Mangoceuticals Inc |
| 05/06/2024 | 4:43PM | Edgar (US Regulatory) | Form PRE 14A - Other preliminary proxy statements | NASDAQ:MGRX | Mangoceuticals Inc |
| 05/02/2024 | 8:00AM | GlobeNewswire Inc. | Mangoceuticals Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement and Conditional Approval of Compliance with Nasdaq’s Minimum Stockholders’ Equity Requirement | NASDAQ:MGRX | Mangoceuticals Inc |
| 04/25/2024 | 8:30AM | GlobeNewswire Inc. | Mangoceuticals Acquires Global Patent Portfolio to Revolutionize Preventive Care | NASDAQ:MGRX | Mangoceuticals Inc |
| 04/12/2024 | 8:45AM | GlobeNewswire Inc. | Mangoceuticals Subsidiary, MangoRx Mexico, Executes Technical Agreement with Mexican Pharmaceutical Manufacturer for Initial Development and Production of its Mango Erectile Dysfunction (ED) Products | NASDAQ:MGRX | Mangoceuticals Inc |
| 03/12/2024 | 9:00AM | GlobeNewswire Inc. | MangoRx Officially Launches ‘PRIME’ by MangoRx, Powered by Kyzatrex®️ FDA Approved Oral Testosterone Replacement Therapy (TRT) Treatment | NASDAQ:MGRX | Mangoceuticals Inc |
| 02/20/2024 | 9:00AM | GlobeNewswire Inc. | MangoRx Launches Direct-To-Clinics Sales Division to Drive and Fuel Customer Acquisition and Revenue Growth | NASDAQ:MGRX | Mangoceuticals Inc |
| 02/13/2024 | 8:00AM | GlobeNewswire Inc. | MANGORX AWARDS SAN FRANCISCO TEAM FREE MANGORX ED PRODUCTS FOR ONE YEAR FOLLOWING BIG GAME LOSS TO KANSAS CITY | NASDAQ:MGRX | Mangoceuticals Inc |
| 02/06/2024 | 9:00AM | GlobeNewswire Inc. | MANGORX TO OFFER THE BIG GAME’S LOSING TEAM A FREE ONE YEAR SUPPLY OF ITS ED PRODUCT, MANGO, TO HELP RAISE… SPIRITS | NASDAQ:MGRX | Mangoceuticals Inc |
| 02/05/2024 | 8:50AM | GlobeNewswire Inc. | MangoRx Accepting Pre Orders for its “PRIME”, by MangoRx, Powered by Kyzatrex®️ FDA Approved Oral Testosterone Replacement Therapy (TRT) Product | NASDAQ:MGRX | Mangoceuticals Inc |
| 01/19/2024 | 8:00AM | GlobeNewswire Inc. | MangoRx’s Brand and Products to be Featured by Barstool Sports in Week of Programming Around the Biggest Sports Event of the Year on February 11 | NASDAQ:MGRX | Mangoceuticals Inc |
| 12/15/2023 | 10:39AM | GlobeNewswire Inc. | Mangoceuticals, Inc. Announces Pricing of $1,200,000 Public Offering | NASDAQ:MGRX | Mangoceuticals Inc |
| 12/13/2023 | 7:30AM | GlobeNewswire Inc. | MANGOCEUTICALS TO INTRODUCE “PRIME”, POWERED BY KYZATREX®️ (CIII TESTOSTERONE UNDECANOATE CAPSULES), FOR AN FDA APPROVED ORAL TESTOSTERONE REPLACEMENT THERAPY (TRT) PRODUCT | NASDAQ:MGRX | Mangoceuticals Inc |